BSE Live
Sep 14, 16:00Prev. Close
0.16
Open Price
0.16
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.18 (20000)
NSE Live
Sep 14, 15:59Prev. Close
0.15
Open Price
0.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Surya Pharmaceutical (in Rs. Cr.) | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 0.00 | -301.81 | -273.16 | 131.72 | 90.46 | |
| Net CashFlow From Operating Activities | 0.00 | 165.55 | 385.56 | 68.93 | 165.31 | |
| Net Cash Used In Investing Activities | 0.00 | -7.90 | -149.98 | -245.00 | -144.32 | |
| Net Cash Used From Financing Activities | 0.00 | -160.30 | -241.17 | 173.64 | -11.32 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 0.00 | -2.65 | -5.60 | -2.43 | 9.68 | |
| Cash And Cash Equivalents Begin of Year | 0.00 | 9.88 | 15.48 | 17.91 | 8.23 | |
| Cash And Cash Equivalents End Of Year | 0.00 | 7.23 | 9.88 | 15.48 | 17.91 |
09.03.2026
09.03.2026
25.02.2026
Surya Roshni Standalone December 2025 Net Sales at Rs 1,927.33 crore, up 3.19% Y-o-Y
17.02.2026
Solar Eclipse highlights: Surya Grahan in its last phase, moon continues to slide away
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities